DK3723752T3 - Nye fast former for cannabidiol og anvendelse heraf - Google Patents
Nye fast former for cannabidiol og anvendelse heraf Download PDFInfo
- Publication number
- DK3723752T3 DK3723752T3 DK18887462.2T DK18887462T DK3723752T3 DK 3723752 T3 DK3723752 T3 DK 3723752T3 DK 18887462 T DK18887462 T DK 18887462T DK 3723752 T3 DK3723752 T3 DK 3723752T3
- Authority
- DK
- Denmark
- Prior art keywords
- cannabidiol
- solid forms
- new solid
- new
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597307P | 2017-12-11 | 2017-12-11 | |
| PCT/US2018/064773 WO2019118360A1 (en) | 2017-12-11 | 2018-12-10 | New solid forms of cannabidiol and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3723752T3 true DK3723752T3 (da) | 2024-11-04 |
Family
ID=66735157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18887462.2T DK3723752T3 (da) | 2017-12-11 | 2018-12-10 | Nye fast former for cannabidiol og anvendelse heraf |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20190177258A1 (da) |
| EP (1) | EP3723752B1 (da) |
| JP (1) | JP7429013B2 (da) |
| KR (1) | KR102898087B1 (da) |
| CN (1) | CN111447929B (da) |
| AU (1) | AU2018383598B2 (da) |
| BR (1) | BR112020011625A2 (da) |
| CA (1) | CA3085331A1 (da) |
| DK (1) | DK3723752T3 (da) |
| ES (1) | ES2992415T3 (da) |
| FI (1) | FI3723752T3 (da) |
| MX (1) | MX2020006071A (da) |
| PT (1) | PT3723752T (da) |
| TW (1) | TWI794361B (da) |
| WO (1) | WO2019118360A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3665145A1 (en) * | 2017-08-07 | 2020-06-17 | Enantia, S.L. | A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol |
| WO2019084292A1 (en) * | 2017-10-25 | 2019-05-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | COMPOSITIONS AND METHODS FOR ADMINISTERING PHARMACEUTICAL AGENTS |
| WO2020089424A1 (en) * | 2018-10-31 | 2020-05-07 | Enantia, S.L. | Solid compositions of cocrystals of cannabinoids |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| US20220332682A1 (en) * | 2019-09-06 | 2022-10-20 | Ebers Tech Inc. | Caanabigerol proline cocrystals |
| US20230381134A1 (en) * | 2020-01-03 | 2023-11-30 | Purisys, Llc | Cocrystals of cannabinoids |
| US10981849B1 (en) * | 2020-02-20 | 2021-04-20 | Sci Pharmtech Inc. | Method for preparing cannabinoids |
| WO2021234449A1 (en) * | 2020-05-19 | 2021-11-25 | Ebers Tech Inc. | Tetrahydrococannabinolic acid cocrystals |
| CN111882044B (zh) * | 2020-08-05 | 2021-09-14 | 四川大学 | 一种基于图神经网络的共晶预测方法、深度学习框架 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| CN114177163B (zh) * | 2022-01-12 | 2023-05-02 | 刘树民 | 一种治疗高血压的药物 |
| WO2025122802A1 (en) * | 2023-12-05 | 2025-06-12 | Artelo Biosciences, Inc. | Increased bioavailability and efficacy of cbd via coadministration with tetramethylpyrazine |
| US20250236581A1 (en) | 2024-01-23 | 2025-07-24 | Manoira Corporation | Cannabidiolic acid cocrystals |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859674A (en) | 1987-06-12 | 1989-08-22 | Houston Biotechnology Incorporated | Pyrazine in prevention and treatment of strokes |
| EP1482917B1 (en) | 2002-02-01 | 2019-05-08 | GW Pharma Limited | Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| GB2393182B (en) * | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
| JP5069905B2 (ja) * | 2003-01-21 | 2012-11-07 | アプテュイト (ウエスト ラファイエット)、エルエルシー | 新規な共結晶化 |
| ATE550022T1 (de) * | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
| US7091205B2 (en) | 2004-10-08 | 2006-08-15 | Yu Show Fu | Use of tetramethylpyrazine in the treatment of brain tumor |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| EP2249837A4 (en) * | 2008-01-31 | 2011-06-15 | Univ Monash | METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| MX2011011445A (es) * | 2009-04-29 | 2011-11-18 | Univ Kentucky Res Found | Composiciones que contienen cannabinoides y metodos para su uso. |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| US20110200531A1 (en) | 2009-09-14 | 2011-08-18 | The Regents Of The University Of California | Treatment and diagnosis of central nervous system disorders |
| BR112012007364A2 (pt) * | 2009-10-23 | 2017-06-06 | Astellas Pharma Inc | composição farmacêutica para administração oral |
| WO2012116349A2 (en) * | 2011-02-26 | 2012-08-30 | Amplio Pharma, Llc | Novel cocrystals of ezetimibe |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US9822384B2 (en) | 2014-07-14 | 2017-11-21 | Librede Inc. | Production of cannabinoids in yeast |
| AU2016215094B2 (en) | 2015-02-05 | 2019-09-26 | Colorado Can Llc | Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA |
| US10399920B2 (en) * | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
| EP3665145A1 (en) * | 2017-08-07 | 2020-06-17 | Enantia, S.L. | A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol |
-
2018
- 2018-12-10 CA CA3085331A patent/CA3085331A1/en active Pending
- 2018-12-10 CN CN201880079622.4A patent/CN111447929B/zh active Active
- 2018-12-10 AU AU2018383598A patent/AU2018383598B2/en active Active
- 2018-12-10 BR BR112020011625-4A patent/BR112020011625A2/pt unknown
- 2018-12-10 DK DK18887462.2T patent/DK3723752T3/da active
- 2018-12-10 TW TW107144375A patent/TWI794361B/zh active
- 2018-12-10 JP JP2020550056A patent/JP7429013B2/ja active Active
- 2018-12-10 US US16/214,913 patent/US20190177258A1/en not_active Abandoned
- 2018-12-10 PT PT188874622T patent/PT3723752T/pt unknown
- 2018-12-10 FI FIEP18887462.2T patent/FI3723752T3/fi active
- 2018-12-10 MX MX2020006071A patent/MX2020006071A/es unknown
- 2018-12-10 WO PCT/US2018/064773 patent/WO2019118360A1/en not_active Ceased
- 2018-12-10 EP EP18887462.2A patent/EP3723752B1/en active Active
- 2018-12-10 ES ES18887462T patent/ES2992415T3/es active Active
- 2018-12-10 KR KR1020207018827A patent/KR102898087B1/ko active Active
-
2019
- 2019-04-26 US US16/396,414 patent/US10604467B2/en active Active
-
2020
- 2020-03-31 US US16/835,383 patent/US11364202B2/en active Active
-
2022
- 2022-06-20 US US17/844,544 patent/US20230404939A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102898087B1 (ko) | 2025-12-09 |
| US20230404939A1 (en) | 2023-12-21 |
| CN111447929A (zh) | 2020-07-24 |
| JP7429013B2 (ja) | 2024-02-07 |
| US11364202B2 (en) | 2022-06-21 |
| ES2992415T3 (es) | 2024-12-12 |
| US20210299048A1 (en) | 2021-09-30 |
| EP3723752A1 (en) | 2020-10-21 |
| WO2019118360A1 (en) | 2019-06-20 |
| JP2021505674A (ja) | 2021-02-18 |
| CA3085331A1 (en) | 2019-06-20 |
| MX2020006071A (es) | 2020-10-28 |
| TW201927733A (zh) | 2019-07-16 |
| CN111447929B (zh) | 2024-05-31 |
| US20190177258A1 (en) | 2019-06-13 |
| BR112020011625A2 (pt) | 2020-11-17 |
| PT3723752T (pt) | 2024-11-07 |
| TWI794361B (zh) | 2023-03-01 |
| EP3723752B1 (en) | 2024-08-21 |
| US20190300466A1 (en) | 2019-10-03 |
| FI3723752T3 (fi) | 2024-11-13 |
| EP3723752A4 (en) | 2021-10-20 |
| US10604467B2 (en) | 2020-03-31 |
| KR20200097285A (ko) | 2020-08-18 |
| AU2018383598B2 (en) | 2024-03-07 |
| AU2018383598A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3723752T3 (da) | Nye fast former for cannabidiol og anvendelse heraf | |
| IL293377B1 (en) | Hsd17b13 variants and uses thereof | |
| DK3615527T3 (da) | Nye azaquinolin-derivater | |
| HUE052373T2 (hu) | Szubsztituált krománok és alkalmazási eljárások | |
| PL3481852T3 (pl) | Nowa neurotoksyna botulinowa i jej pochodne | |
| EP3526222A4 (en) | TYK2 INHIBITORS AND THEIR USES | |
| EP3528816A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| PL4393545T3 (pl) | Nowe zastosowania pochodnych piperydynylo-indolowych | |
| DK3497117T5 (da) | Nye alkalisk stabile immunglobulin-bindende proteiner | |
| IL253463A0 (en) | Binding-triggered transcriptional switches and methods of use thereof | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3555076T3 (da) | Nye phenylpropionsyrederivater og anvendelser deraf | |
| DK3565806T3 (da) | Nye phenylderivater | |
| DK3368014T3 (da) | Nye formuleringer af cannabinoider | |
| DK3365339T3 (da) | Nye ferroportin-hæmmere | |
| EP3478308A4 (en) | CANNABIS-BASED COMPOSITION AND PROCESSES | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| PL3167096T3 (pl) | Dwuetapowy sposób nanoszenia | |
| DK3160966T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3509591T3 (da) | Nye jak1-selektive inhibitorer og anvendelser deraf | |
| DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
| GEAP201914237A (en) | Heteroaryls and uses thereof | |
| PL3676027T3 (pl) | Sposób klasyfikacji i urządzenie | |
| DK3443010T3 (da) | Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf | |
| DK3233111T3 (da) | Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf |